Trevi Therapeutics, Inc. Investment Income, Interest
Trevi Therapeutics, Inc. (TRVI) reported Investment Income, Interest of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- Trevi Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.70M, a 91.61% increase year-over-year.
- Trevi Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.70M, a 50.76% increase year-over-year.
- Trevi Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.90M, a 125.74% increase year-over-year.
- Trevi Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $2.10M, a 154.36% increase year-over-year.
- Trevi Therapeutics, Inc. investment income, interest for fiscal 2025 was $6.54M, a 81.45% increase from fiscal 2024.
- Trevi Therapeutics, Inc. investment income, interest for fiscal 2024 was $3.60M, a 24.14% decline from fiscal 2023.
- Trevi Therapeutics, Inc. investment income, interest for fiscal 2023 was $4.75M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $4.39M 10-Q · filed 2026-08-06 | $6.29M derived: sum of 3 quarters · filed 2026-08-06 | $8.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-05 | $3.60M derived: sum of 2 quarters · filed 2026-05-05 | $5.70M derived: sum of 3 quarters · filed 2026-05-05 | $7.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.00M derived: sum of 2 quarters · filed 2026-03-17 | $5.41M derived: sum of 3 quarters · filed 2026-08-06 | $6.54M 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.10M 10-Q · filed 2025-11-13 | $3.51M derived: sum of 2 quarters · filed 2026-08-06 | $4.63M 10-Q · filed 2025-11-13 | $5.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.41M 10-Q · filed 2026-08-06 | $2.53M 10-Q · filed 2026-08-06 | $3.38M derived: sum of 3 quarters · filed 2026-08-06 | $4.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-05 | $1.97M derived: sum of 2 quarters · filed 2026-05-05 | $2.79M derived: sum of 3 quarters · filed 2026-05-05 | $3.73M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.67M derived: sum of 2 quarters · filed 2026-03-17 | $2.60M derived: sum of 3 quarters · filed 2026-03-17 | $3.60M 10-K · filed 2026-03-17 |
| 2024-09-30 | $826.00K 10-Q · filed 2025-11-13 | $1.76M derived: sum of 2 quarters · filed 2025-11-13 | $2.76M 10-Q · filed 2025-11-13 | $3.90M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $935.00K 10-Q · filed 2025-08-07 | $1.93M 10-Q · filed 2025-08-07 | $3.07M derived: sum of 3 quarters · filed 2025-08-07 | $4.25M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $998.00K 10-Q · filed 2025-05-08 | $2.13M derived: sum of 2 quarters · filed 2025-05-08 | $3.32M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $2.32M derived: sum of 2 quarters · filed 2025-03-18 | $4.75M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $1.18M 10-Q · filed 2024-11-06 | $3.61M 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |